Bioasis Technologies, Inc. (OTCMKTS: BIOAF) is a biotechnology company dedicated to developing therapies and diagnostic agents that effectively cross the blood–brain barrier (BBB). Leveraging its proprietary xB3™ platform, Bioasis designs biologics and small molecules with enhanced central nervous system (CNS) delivery capabilities. The company’s core mission is to address neurological disorders that have historically been challenging to treat due to limited drug penetration into the brain.
At the center of Bioasis’s pipeline is its lead program for Parkinson’s disease, which employs the xB3 delivery technology to transport therapeutic antibodies directly to affected brain regions. In addition to Parkinson’s therapeutics, Bioasis is advancing diagnostic imaging agents intended to improve early detection of Alzheimer’s disease and other neurodegenerative conditions. The company’s platform has also shown promise in veterinary medicine, where it supports treatments for canine cognitive dysfunction.
Headquartered in Vancouver, Canada, Bioasis collaborates with pharmaceutical and biotechnology partners worldwide, offering out-licensing opportunities and joint development agreements. Its research and development efforts are carried out in collaboration with leading academic institutions and contract research organizations across North America and Europe. These strategic partnerships aim to expand the reach of the xB3 platform and accelerate clinical programs.
Founded in the early 2000s, Bioasis traces its origins to blood–brain barrier research conducted at the University of Toronto and Sunnybrook Research Institute. The company is led by President and CEO Jeff Graham, who brings extensive experience in biotech leadership, and advises a scientific board that includes experts in neurology, pharmacology, and translational research. Under this leadership, Bioasis continues to pursue innovative solutions for CNS disorders and to build a pipeline of differentiated drug candidates.
AI Generated. May Contain Errors.